ENDRA LIFE SCIENCES INC (NDRA)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$6.05+6.51%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
Broken: Primary pillar broken — Reduce cash burn to less than -$1.12M in operating cash flow: OCF -$16.8M vs -$1.1M.
ENDRA is working on a merger to improve its business. It has cut costs, reducing cash burn from -$1.62M to -$1.12M in operating cash. Net losses narrowed from -$3.17M to -$1.31M, showing progress. The company also announced a share buyback program, signaling capital allocation focus.
The company remains loss-making with negative EPS expected through 2027. It faces Nasdaq listing risks due to low stockholders' equity. The recent sharp share price drop reflects market doubts about its turnaround and merger success.
The market reflects a sharp selloff and high risk given the company's losses and regulatory challenges. There is no clear consensus revenue growth or fair value, indicating uncertainty. Our view sees some progress but still significant risks ahead.
Breaks if: Merger agreement is terminated or fails to close by end of 2026
Breaks if: Stockholders' equity remains below $2.5M by end of 2026
Breaks if: net loss exceeds -$1.31M in any quarter after 2026-Q2
Breaks if: operating cash flow falls below -$1.12M in any quarter after 2026-Q2
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity with high risk. The current thesis state indicates volatility in management and recent weak financial results, which raises concerns.
The market seems to have priced in low expectations due to NDRA's loss-making status and recent earnings misses. However, the healthcare sector's positive backdrop may provide some support for NDRA's performance.
Fundamentals are likely to remain under pressure in the near term, given the high probability of an earnings miss. Management's focus on cost control and capital allocation may help, but recent financial performance has been weak.
The thesis hinges on the performance of sector bellwethers like TMO, DHR, and NTRA. If these companies continue to perform well, NDRA may benefit from the sector momentum, but any deterioration could negatively impact NDRA.
In the 1 to 3 year view, NDRA's prospects depend heavily on sector performance and management execution amid high risks. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings beat is a positive sign. However, NDRA experienced a sharp drop, which may indicate a repricing of the thesis. This price movement raises concerns about the company's stability and future performance.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.